Cenicriviroc is a dual CCR2 and CCR5 antagonist with significant antifibrotic and anti-inflammatory activity in models of fibrosis, such as the mouse peritonitis model, mouse diet-induced NASH model, and rat thioacetamide-induced liver fibrosis model (171). The gene discussed is CCR5; the disease is metabolic dysfunction-associated steatohepatitis.